RaQualia Pharma Inc. (TYO:4579)

Market Cap	13.45B
Revenue (ttm)	3.23B
Net Income (ttm)	-526.00M
Shares Out	24.46M
EPS (ttm)	-23.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,400
Average Volume	312,560
Open	571.00
Previous Close	576.00
Day's Range	548.00 - 581.00
52-Week Range	301.00 - 728.00
Beta	0.75
RSI	50.87
Earnings Date	Aug 14, 2025

About RaQualia Pharma

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. The company also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 64
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4579

Financial Performance

In 2024, RaQualia Pharma's revenue was 3.11 billion, an increase of 63.44% compared to the previous year's 1.90 billion. Losses were -495.00 million, 53.3% more than in 2023.